Resumen de acción 5DG Ocumension Therapeutics, junto con sus filiales, opera como empresa de plataforma farmacéutica oftálmica en la República Popular China. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Ocumension Therapeutics Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Ocumension Therapeutics Precios históricos de las acciones Precio actual de la acción HK$0.52 Máximo en las últimas 52 semanas HK$0.86 Mínimo de 52 semanas HK$0.44 Beta 0.82 Cambio en 1 mes -1.89% Variación en 3 meses -15.45% Cambio de 1 año -7.14% Variación en 3 años -58.40% Variación en 5 años n/a Variación desde la OPV -86.16%
Noticias y actualizaciones recientes
Ocumension Therapeutics Announces Change of Non-Executive Director Jan 16
Ocumension Therapeutics Announces Patient Enrollment Completed in the Second Phase III Clinical Trial of OT-301 in China Dec 03
Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director Oct 21
New minor risk - Shareholder dilution Oct 20
Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration Sep 24
Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration Sep 19 Ver más actualizaciones
Ocumension Therapeutics Announces Change of Non-Executive Director Jan 16
Ocumension Therapeutics Announces Patient Enrollment Completed in the Second Phase III Clinical Trial of OT-301 in China Dec 03
Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director Oct 21
New minor risk - Shareholder dilution Oct 20
Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration Sep 24
Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration Sep 19
New minor risk - Profitability Aug 15
First half 2024 earnings released: CN¥0.23 loss per share (vs CN¥0.32 loss in 1H 2023) Aug 14
Now 21% undervalued after recent price drop Aug 05
Ocumension Therapeutics to Report First Half, 2024 Results on Aug 12, 2024 Jul 30
Ocumension Therapeutics Announces Biologic License Application for OT-702 Accepted by the National Medical Products Administration Jul 17
Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024 May 25
Full year 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.64 loss in FY 2022) Apr 30
Now 21% undervalued after recent price drop Mar 27
Full year 2023 earnings released: CN¥0.59 loss per share (vs CN¥0.64 loss in FY 2022) Mar 24
Forecast to breakeven in 2025 Mar 24
New major risk - Revenue and earnings growth Mar 23
Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202 Mar 14
Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024 Mar 08 Ocumension Therapeutics (SEHK:1477) commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023. Dec 14
Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China Nov 30
Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China Nov 23
Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023 Oct 01
New minor risk - Profitability Aug 28
First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022) Aug 27
Ocumension Therapeutics to Report First Half, 2023 Results on Aug 24, 2023 Aug 15
Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S Jul 23
Forecast to breakeven in 2025 Jul 07
Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101 Jun 02
Full year 2022 earnings released: CN¥0.64 loss per share (vs CN¥0.43 loss in FY 2021) Mar 31
Ocumension Therapeutics Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended December 31, 2022 Feb 15
Forecast to breakeven in 2024 Feb 06
Ocumension Therapeutics Provides Update on Phase I Clinical Trial of Ot-202 Feb 04
Ocumension Therapeutics Announces Patient Enrollment Complete in the Phase III Clinical Trial of OT-101 in China Feb 02
Now 21% undervalued after recent price drop Jan 11
Less than half of directors are independent Nov 16
First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.12 loss in 1H 2021) Aug 28
Ocumension Therapeutics to Report First Half, 2022 Results on Aug 26, 2022 Aug 17
Ocumension Therapeutics Receives Approval from the National Medical Products Administration for Yutio Chronic Non-Infectious Uveitis Jun 24
EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye Jun 22
Ocumension Therapeutics Announces Executive Changes Jun 16
Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-703 in China Jun 10
Ocumension Therapeutics Receives Approval from the National Medical Products Administration for its IND Application to Begin the Phase Iii Clinical Study for Fluocinolone Acetonide Intravitreal Implant Jun 09
Less than half of directors are independent Apr 27
Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee Apr 09
Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee Apr 01
Forecast to breakeven in 2024 Mar 30
Ocumension Therapeutics Voluntary Announcement primary Clinical Endpoint Achieved in the Phase III clinical Trial of OT-1001 Mar 04
Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China Mar 03
Ocumension Therapeutics Announces First Patient Enrolled in the Clinical Trial of self-Developed Class I New Drug OT-202 in China Jan 05
First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020) Sep 24
Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical Trial OT-502 (DEXYCU®) in China Sep 15
First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020) Aug 23
Ocumension Therapeutics MHRA Approval Received for Phase III Clinical Trial of OT-101 in the United Kingdom Aug 04
Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-101 Jul 15
Ocumension Therapeutics Announces Clinical Trial Authorization for Initiatinga Phase III Clinical Trial of OT-101 Accepted in United Kingdom May 21
Ocumension Therapeutics Announces Investigational New Drug Application for Initiating A Multi-Regional Phase Iii Clinical Trial in the People's Republic of China for OT-101 May 12
Non-Executive Director has left the company Mar 24
Ocumension Therapeutics Announces Board Changes Mar 21
Ocumension Therapeutics, Annual General Meeting, Jun 29, 2021 Mar 20
New 90-day low: €2.32 Mar 12
Ocumension Therapeutics to Report Fiscal Year 2020 Results on Mar 19, 2021 Mar 10
Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phase 3 Trial Mar 05
Ocumension Therapeutics Announces Second Phase III Clinical Trial of OT-301 Approved in China Mar 04
Ocumension Therapeutics Announces Investigational New Drug Approval for Initiating A Multi-Regional Phase III Clinical Trial Feb 23
Ocumension Therapeutics Announces Phase III Clinical Trial of the Recently In-Licensed Drug Candidate of the Group Feb 10
Ocumension Therapeutics has completed a Follow-on Equity Offering in the amount of HKD 1.5876 billion. Jan 24
Ocumension Therapeutics announced that it expects to receive HKD 793.8 million in funding from 6 Dimensions Capital, L.P. Jan 14
New 90-day high: €3.00 Jan 12 Ocumension Therapeutics Announces First Patient Enrolled in the Phase III Clinical Trial of OT-1001 (Zerviate) in China
New 90-day high: €2.70 Dec 22
Ocumension Therapeutics Initiates the Real World Study of Its Core Product, OT-401 (YUTIQ) in Boao Super Hospital in Hainan Province, China Dec 02
Ocumension Therapeutics Receives Approval by Chinese Authorities for Local Start of Mont Blanc Phase 3 Trial Oct 27
New 90-day low: €2.30 Oct 24
Ocumension Therapeutics Receives Approval from China’S Center for Drug Evaluation of the National Medical Products Administration Sep 22
Ocumension Therapeutics to Report First Half, 2020 Results on Aug 26, 2020 Aug 18
Ocumension Therapeutics announced that it has received $20 million in funding Jul 17 Rentabilidad de los accionistas 5DG DE Pharmaceuticals Mercado DE 7D 4.4% 4.4% 2.0% 1Y -7.1% -5.8% 15.2%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: 5DG superó a la industria German Pharmaceuticals, que obtuvo un rendimiento del -5.8% el año pasado.
Rentabilidad vs. Mercado: 5DG obtuvo unos resultados inferiores a los del mercado German, que fueron del 15.2% el año pasado.
Volatilidad de los precios Is 5DG's price volatile compared to industry and market? 5DG volatility 5DG Average Weekly Movement 6.3% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.0% 10% least volatile stocks in DE Market 2.4%
Precio estable de las acciones: 5DG no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado German.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 5DG (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Ocumension Therapeutics, junto con sus filiales, opera como empresa de plataforma farmacéutica oftálmica en la República Popular China. Descubre, desarrolla y comercializa terapias para pacientes oftalmológicos. Su cartera incluye productos y fármacos para el tratamiento de la uveítis crónica no infecciosa, la blefaritis, la conjuntivitis infecciosa y alérgica, el edema macular diabético, el ojo seco, el glaucoma y la hipertensión ocular, la inflamación postoperatoria, la neovascularización coroidea, la conjuntivitis bacteriana, la retinosis pigmentaria, el glaucoma agudo, la degeneración macular asociada a la edad, el rechazo de injertos de córnea, la miopía y la neuritis óptica.
Mostrar más Resumen de fundamentos de Ocumension Therapeutics ¿Cómo se comparan los beneficios e ingresos de Ocumension Therapeutics con su capitalización de mercado? Estadísticas fundamentales de 5DG Capitalización bursátil €436.64m Beneficios(TTM ) -€42.77m Ingresos (TTM ) €41.12m
10.6x Ratio precio-ventas (PS)
-10.2x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de 5DG Ingresos CN¥310.29m Coste de los ingresos CN¥129.44m Beneficio bruto CN¥180.86m Otros gastos CN¥503.58m Beneficios -CN¥322.73m
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.40 Margen bruto 58.29% Margen de beneficio neto -104.01% Ratio deuda/patrimonio 0%
¿Cómo se ha desempeñado 5DG a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/01/30 10:04 Precio de las acciones al final del día 2025/01/30 00:00 Beneficios 2024/06/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Ocumension Therapeutics está cubierta por 5 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Yanyin Zhu China International Capital Corporation Limited Fang Quan China International Capital Corporation Limited Ziyi Chen Goldman Sachs
Mostrar 2 más analistas 
